General
Preferred name
SUVOREXANT
Synonyms
Belsomra ()
MK4305 ()
MK-4305 ()
P&D ID
PD009398
CAS
1030377-33-3
Tags
available
drug
Approved by
FDA
First approval
2014
Drug Status
investigational
approved
Drug indication
Insomnia
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Suvorexant is the first approved orexin receptor antagonist drug. It is non-selective, being an equipotent antagonist of OX1 and OX2. The acronym for dual orexin receptor antagonist compounds/drugs is DORA.
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
20
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
The Spectrum Collection
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
30
Molecular Weight
450.16
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
5
Aromatic Ring Count
4
cLogP
4.11
TPSA
80.29
Fraction CSP3
0.3
Chiral centers
1.0
Largest ring
7.0
QED
0.47
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Member status
virtual
MOA
Orexin Receptor Antagonists
Orexin 1 receptor antagonist, Orexin 2 receptor antagonist
Source data
